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Background: Caesarean section (CS) rates are rising worldwide. In the Netherlands, the most significant rise is
observed in healthy women with a singleton in vertex position between 37 and 42 weeks gestation, whereas it is
doubtful whether an improved outcome for the mother or her child was obtained. It can be hypothesized that
evidence-based guidelines on CS are not implemented sufficiently.
Therefore, the present study has the following objectives: to develop quality indicators on the decision to perform
a CS based on key recommendations from national and international guidelines; to use the quality indicators in
order to gain insight into actual adherence of Dutch gynaecologists to guideline recommendations on the
performance of a CS; to explore barriers and facilitators that have a direct effect on guideline application regarding
CS; and to develop, execute, and evaluate a strategy in order to reduce the CS incidence for a similar neonatal
outcome (based on the information gathered in the second and third objectives).
Methods: An independent expert panel of Dutch gynaecologists and midwives will develop a set of quality
indicators on the decision to perform a CS. These indicators will be used to measure current care in 20 hospitals
with a population of 1,000 women who delivered by CS, and a random selection of 1,000 women who delivered
vaginally in the same period. Furthermore, by interviewing healthcare professionals and patients, the barriers and
facilitators that may influence the decision to perform a CS will be measured. Based on the results, a tailor-made
implementation strategy will be developed and tested in a controlled before-and-after study in 12 hospitals (six
intervention, six control hospitals) with regard to effectiveness, experiences, and costs.
Discussion: This study will offer insight into the current CS care and into the hindering and facilitating factors
influencing obstetrical policy on CS. Furthermore, it will allow definition of patient categories or situations in which
a tailor-made implementation strategy will most likely be meaningful and cost effective, without negatively
affecting the outcome for mother and child.
Trial registration: www.clinicaltrials.gov: NCT01261676* Correspondence: s.melman@mumc.nl
†Equal contributors
1GROW- School for Oncology and Developmental Biology, Department of
Obstetrics and Gynaecology, Maastricht University Medical Centre, P.O. Box
5800, Maastricht, AZ 6202, The Netherlands
Full list of author information is available at the end of the article
© 2013 Melman et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Melman et al. Implementation Science 2013, 8:3 Page 2 of 8
http://www.implementationscience.com/content/8/1/3Background
The worldwide rise in caesarean section (CS) rate is a
major healthcare issue, with rates reported as high as
32% in the United States (US) and 37% in Brazil [1,2].
In the Netherlands, the overall CS rate has increased
from 8.1% to 13.6% over the recent decade. Although
this rise is relatively low compared to other countries, a
striking detail is that the most impressive rise, in absolute
numbers, was among healthy women with a singleton in
vertex position between 37 and 42 weeks gestation [3].
However, an increasing CS rate does not imply an
improved outcome for mother and infant [4]. CS are
associated with an increased risk of maternal mortality
as well as serious morbidity, such as admission to the
intensive care unit (Odds Ratios (ORs) between 30.8 and
63.4), hysterectomy (ORs between 3.2 and 13.5), and puer-
peral infection (OR 3.0) [5-7].
Besides the short-term risks, CS have an impact on the
mother’s future reproductive health, for example uterine
rupture, placenta praevia, or placenta accreta [8,9].
There is no evidence suggesting a better neonatal out-
come from the increased CS rate in terms of mortality,
intracranial haemorrhage, or impaired neurological de-
velopment in the general population [10,11]. In fact, an
elective CS performed before 39 completed weeks is
associated with respiratory distress and admission to the
neonatal intensive care unit [11,12].
The question arises what causes the worldwide in-
crease in CS rate considering the fact that in most situa-
tions there are no apparent benefits of a CS for mother
and child; the costs are higher compared to vaginal birth
[5]; and the incidence of both maternal and neonatal
complications are increased. There are concerns about
the increasing rate of planned CS as well as a declining
rate of vaginal birth after a previous CS (VBAC) in the
US and Australia [13,14].
To optimize CS practice, the Royal College of Obstetri-
cians and Gynaecologists (RCOG) developed an evidence-
based guideline (NICE: National Institute of Clinical
Evidence) with clear recommendations for obstetric care.
Similar recommendations, which have a direct effect on
the decision to perform a CS, are also mentioned in the
different guidelines of the Dutch Society of Obstetrics
and Gynaecology (NVOG), Society of Obstetricians and
Gynaecologists of Canada (SOGC), American College
of Obstetrics and Gynaecology (ACOG), and National
Guideline Clearinghouse from the US department of
health and human services (NGC).
Despite the introduction of evidence-based guidelines,
the CS rate continues to increase. We hypothesize that
poor adherence to the guidelines plays a key role in the
rising CS rate. In order to optimize adherence to the CS
guidelines, the stepwise model by Grol can be used to
select the proper strategies [15,16]. The first step in thismodel is to analyze the current care (measured by valid
quality indicators) compared to the optimal care as
described in evidence-based guidelines, and to determine
which barriers and facilitators might influence the imple-
mentation of optimal care. Subsequently, a tailor-made
implementation strategy can be developed with activities
applied to the determined barriers. In the last step, the
strategy is executed and evaluated in terms of effective-
ness, feasibility, and costs.
In view of the rising CS rate, this study aims are:
1. To develop a set of quality indicators on the decision
to perform a CS based on key recommendations of
both Dutch and international guidelines.
2. To gain insight into actual adherence of Dutch
gynaecologists to guideline recommendations on the
performance of CS.
3. To explore barriers and facilitators that have a direct
effect on application of guideline recommendations
regarding CS.
4. To develop, execute and evaluate a strategy in order
to improve care and possibly decrease the CS
incidence for a similar neonatal outcome, based on
the information gathered in steps two and three.
Methods
The four aims were approached in four parts: the devel-
opment of quality indicators, the assessment of current
care, the identification of barriers and facilitators, and
the development of a tailored implementation strategy
and executing and evaluating this strategy in a clustered
controlled before-and-after study (CBA).
The development of quality indicators
Design and methods
In order to measure current Dutch practice on CS, quality
indicators regarding the process, structure, and outcome
of care need to be developed. This will be achieved
according to the RAND-modified Delphi method [17,18].
The indicators will be based on key recommendations
extracted from the guidelines of several international
obstetric organisations (RCOG, NVOG, SOGC, ACOG
and NGC). These key recommendations will be evaluated
in two rounds by an independent expert panel consisting
of Dutch obstetricians and midwives. In the first round, a
questionnaire will be developed on three subjects (planned
CS, emergency CS, and methods to reduce the CS rate).
The questionnaire will be sent to the experts who will be
asked to individually rate the key recommendations on a
9-point Likert scale ranging from 1 to 9 (‘not relevant’ to
‘extremely relevant’ for measuring the quality of CS care).
Furthermore, a ranking of the key recommendations will
be asked per subject to ultimately extract those indicators
considered to be most important for quality-of-care
Table 1 Ten-group classification according to Robson
Groups:
1. Nulliparous, single cephalic, >37 weeks, in spontaneous labour
2. Nulliparous, single cephalic, >37 weeks, induced or CS before
labour
3. Multiparous (excluding previous CS), single cephalic, >37 weeks, in
spontaneous labour
4. Multiparous (excluding previous CS), single cephalic, >37 weeks,
induced or CS before labour
5. Previous CS, single cephalic, >37 weeks
6. All nulliparous breeches
7. All multiparous breeches (including previous CS)
8. All multiple pregnancies (including previous CS)
9. All abnormal lies (including previous CS)
10. All single cephalic, < 36 weeks, (including previous CS)
Table 2 Inclusion criteria for severe acute maternal
morbidity
Group 1: ICU admission
- Admission to ICU or coronary care unit, other than for standard
postoperative recovery
Group 2: Uterine rupture
- Clinical symptoms (pain, fetal distress, acute loss of contractions and
haemorrhage) that led to an emergency CS, at which the presumed
diagnosis of uterine rupture was confirmed
- Peripartum hysterectomy or laparotomy for uterine rupture
Group 3: Eclampsia/ HELLP syndrome
- Eclampsia
- HELLP syndrome only when accompanied by liver haematoma or
rupture
Group 4: Major obstetric haemorrhage
- Transfusion need of > 4 units of packed cells
- Embolisation or hysterectomy for major obstetric haemorrhage
Group 5: Miscellaneous
- Other cases of severe maternal morbidity to the opinion of the
treating obstetrician, not to be included in group 1-4
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add comments or suggest additional recommendations
they consider suitable as a quality indicator. The returned
questionnaires will be analysed based on the ratings of the
recommendations on the 9-point Likert scale, and the me-
dian score of these items will be calculated and rated as
described previously by Campbell [19]. Furthermore, scor-
ing variables reflecting the ranking of the items in each of
the three subjects will be developed (e.g., in a top 3 rank-
ing, a first ranking creates 3 points, a second ranking 2
points, and a third ranking 1 point).
The second round consists of a consensus meeting
where the experts will receive their individual as well as
the overall results of the first round to promote discus-
sion. The aim of this meeting is to reach consensus on
those recommendations that are most suitable for asses-
sing the quality of care on performing CS. After consensus
is reached, the recommendations will be operationalized
into a set of measurable quality indicators.
Study population and setting
A representative, national expert panel consisting of
obstetricians and midwives (about 12 to 15 experts) will
be invited. The obstetricians and midwives will have
worked at various types of hospitals, ranging from small
regional hospitals to university hospitals.
Outcome measures
The outcome of the first step of the study is a set of valid
quality indicators regarding the decision to perform a CS
which can then be used to measure the current practice.
The assessment of current care
Design and methods
A retrospective medical record search based on the set
of quality indicators will be performed in order to assess
the Dutch gynaecologists’ adherence to the CS guideline
recommendations. Adherence to these indicators will be
quantified, as well as the variation in care and adherence
between the participating hospitals. To gain insight into
the current Dutch care compared to international care,
the CS percentages of the different risk groups will be
calculated according to the Robson classification
(Table 1) [20]. Furthermore, the maternal mortality or
severe acute morbidity (Table 2) [21], and perinatal
mortality or serious morbidity (pH <7.00, Apgar 5 min
<7, and NICU admission) will be noted. This study will
provide us with information about current practice on
CS in the Netherlands and insight into the effects on
outcome of mother and child.
Study population and setting
In order to create a representative view of the current
obstetrical care in The Netherlands, a multi-centre studywill be carried out. Twenty hospitals of different Dutch
regions will participate in this study, including university
teaching hospitals, non-university teaching hospitals
and non-university, non-teaching hospitals. The present
study will take place in the setting of a Dutch Obstetric
Research Consortium in which all the participating
hospitals collaborate.
In the participating hospitals, data on basic obstetrical
care and adherence to the quality indicators will be col-
lected. Per hospital 100 women will be selected from the
local database: 50 women who delivered by CS and a
random set of 50 women who delivered vaginally in the
same time period. Exclusion criteria will be a major fetal
congenital malformality and fetal death prior to onset
of delivery.
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The main outcome is adherence to the guideline recom-
mendations, based on the adherence to the quality indi-
cators. Therefore, basic obstetrical data and indicator
specific data will be gathered. For example, consider the
indicator ‘every woman with a child in breech presenta-
tion at 34 to 36 weeks gestation should be offered external
cephalic version unless a contraindication for external
cephalic version is present.’ This implies that we need to
assess the incidence of breech presentation at 34 to 36
weeks gestation, as well as data that show whether an
external cephalic version is being offered. Furthermore,
we will note in which cases this procedure was not offered
for a valid reason. This will allow us to determine the
frequencies of adherence for this indicator.
The secondary outcomes are the number of preventable
CS, and Dutch practice as compared to international data
using the Robson criteria.
Sample size considerations
Assuming an adherence to the guidelines of 75%, an
alpha of 0.05, and a precision of the estimation of 5%,
300 patients must be included. However, this number
has to be adapted to take clustering of data across clini-
cians and within obstetrical departments into account.
Assuming an intra-cluster correlation (ICC) of 0.2 and
80 professionals in 20 hospitals, 960 medical records
need to be analysed. In order to compensate for loss to
follow-up or incomplete data, 1,000 women with a CS
will be included in 20 hospitals within a timescale of
three to four months. In order to enable the calculation
of specific events, as described in ‘outcome measures,’ a
random selection of 1,000 women with a vaginal birth
will be included. Thus, there will be 2,000 participants,
i.e., 1,000 women after a caesarean delivery and 1,000
women after a vaginal birth. Sampling fraction will be
adjusted to the fraction of women with CS in each indi-
vidual hospital.
Data analysis
The frequencies of adherence per quality indicator will
be calculated. This will be calculated by dividing the
total number of women who apply for an indicator and
for whom care was appropriate by the total number of
women who apply for an indicator. For example, women
with a child in breech presentation between 34 to 36
weeks of gestation, without contraindication for external
cephalic version, should have been offered an external
cephalic version. Adherence is the total number of
women with a child in breech presentation between 34
to 36 weeks of gestation without contraindication for ex-
ternal cephalic version, in whom an external version was
offered, divided by the total number of women with a
child in breech presentation between 34 to 36 weeks ofgestation without contraindication for external cephalic
version.
Barrier and facilitator study
Design and methods
To determine the barriers and facilitators that influence
the decision to perform a CS for healthcare professionals
and patients, a qualitative study will be performed. The
setting for guideline implementation will be analysed.
Focus group interviews will be held among healthcare
professionals (obstetricians, residents, and midwives) to
discover factors that determine the decision to perform
a CS or not. The interviewer will explore the following
categories of influencing factors: features of the guide-
lines itself; features of the target group of professionals
who should use the guidelines; features of patients who
have to accept or contribute to the use of the guidelines;
features of the social setting and social network of the
professionals; and features of the organizational, eco-
nomic, and administrative context. Remarks by profes-
sionals will be classified into categories of potential
determining factors following this theoretical framework.
The ‘prevalence’ of the features mentioned in the focus
group interviews will be quantified in a survey with
questionnaires among the different professionals.
Similarly, depending on the outcome of the current
care study, semi-structured interviews will be held with
patients in a detailed study to discover relevant factors
that influence the patients’ decision to choose a CS or
vaginal delivery.
Study population and setting
In different hospital types (university, non-university
teaching, and non-university non-teaching hospitals)
interviews will be held among healthcare professionals
(obstetricians, residents and midwives) as well as patients.
Focus group interviews among 8 to 12 healthcare pro-
fessionals will be planned. To assess whether the factors
mentioned in the focus group interviews are structural,
the ’prevalence’ of these factors will be assessed using a
survey with questionnaires among obstetric gynaecolo-
gists, residents, and midwives in the Netherlands. The
questionnaires will be sent to the professionals via email
addresses we will obtain from the national professional
organisations of both professions. Among patients,
semi-structured interviews will be held. These patients
will be selected in the abovementioned hospitals from
the current care study. The interviews will be conducted
with those women belonging to the non-adherence sub-
groups (such as breech, non-progressing labour, or ma-
ternal request) to whom a possible implementation
should be directed. Approximately ten to fifteen women
will be interviewed until no new information emerges
during the interviews.
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The main outcome measures are the barriers and facili-
tators for adherence to the quality indicators for per-
forming a CS.
Data analysis
Using Atlas, the qualitative software package, a qualitative
analysis will be performed on the barriers and facilitators
that are presented in the interviews among healthcare
professionals and patients. The transcribed interview will
be marked and coded with barriers and facilitators accord-
ing to the framework used to structure the interviews:
features of the guidelines, professionals, patients, social
setting, and organization. These influencing factors will be
quantified among all Dutch gynaecologists and midwives
by means of questionnaires. The analyses of the question-
naires will be descriptive (e.g., frequencies and means).
Controlled before-and-after study
Design and methods
Based on the results of the current care study and the
barrier and facilitator study, one or more target groups
for a tailor-made implementation strategy will be identi-
fied. Target groups will be selected with focus on women
with both a high incidence of the indicator (our hypothesis
is that this will include, for example, non-progressing
labour and previous CS) and low indicator adherence. A
tailor-made implementation strategy will be developed in
order to increase adherence to the CS quality indicators.
This strategy will be executed and evaluated in a clustered
CBA study in 12 hospitals (six intervention, six control
hospitals) (see sample size calculation) in terms of effect-
iveness, experiences, and costs. It is likely that a strategy
with different implementation elements is needed because
several barriers for implementation of recommendations
may exist at different levels. This will probably result in a
combined intervention directed at the level of profes-
sionals, patients, and the organisation.
Study population and setting
The implementation strategy will be executed and evalu-
ated in 12 hospitals (see sample size calculation) that
also participated in the current care study: six interven-
tion hospitals in which the newly developed strategy will
be applied; and six control hospitals in which care as
usual will be offered. In order to select these 12 hospi-
tals, all 20 hospitals of the current care study will be
categorized into university, non-university teaching, and
non-university non-teaching hospitals (three categories).
Within these three categories, possible hospital pairs will
be made based on pre-intervention adherence to quality
indicators and CS rates, as measured in the current care
study. To get a sample representative for the Dutch set-
ting, in total two university hospitals, six non-universityteaching hospitals and four non-university, non-teaching
hospitals will be asked to participate. Subsequently, the
participating hospitals have to be assigned to the interven-
tion and control group. This will be done per stratum and
based on geographic region. The evaluation will include
an effect, process, and cost analysis. Just as in de current
care study, the effects will be measured both at medical
outcome level (i.e., CS rates and complication rates) and
on guideline adherence level. Satisfaction with and applic-
ability of the tailor-made implementation strategy for both
patients and healthcare professionals will be measured in
a process evaluation. Information regarding the process
will be gathered in a qualitative study in the hospitals in
which the implementation strategy was applied. Individual
interviews will take place among the involved healthcare
professionals and patients to gather data about experi-
ences with the changed care. During the interview, they
also will be asked about which elements of the tested
strategy they specifically used to implement the evidence-
based guidelines; how satisfied they are with the different
elements; and their opinion about the feasibility of the dif-
ferent elements.
Furthermore, a cost analyses of the tested implemen-
tation strategy will take place with respect to three
aspects: 1) the rate at which the guideline recommenda-
tions are already applied; 2) the costs of the implemen-
tation strategy (taking into account the development of
the strategy, training of healthcare professionals, and
possible extra costs regarding both time and medical
costs) and 3) the effectiveness of the implementation
strategy. In order to measure the effectiveness of the
implementation strategy both the effects on medical
outcome (i.e., CS rates, complication rates) and adher-
ence to CS quality indicators will be measured. The
cost-effectiveness of the implementation strategy will be
expressed as the incremental costs per extra patient
treated according to the CS quality indicators, com-
pared to the ‘do-nothing’ strategy.
Outcome measures
The primary outcome is effectiveness of the implemen-
tation strategy, which is defined as the observed in-
crease in adherence to the developed quality indicators
with regard to the chosen target group (for example
non-progressing labour or previous CS) between the
intervention and control hospitals and the actual CS
rates in both groups. Secondary outcome measures are
experiences and satisfaction of healthcare providers and
patients with the implementation strategy as well as
applicability and costs.
Sample size considerations
For a sample size calculation, the target group and the
adherence to the quality indicators regarding this target
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performing the current care as well as the barrier study.
Based on these data, the sample size can be calculated.
In this calculation, we will take into account clustering
of patients within professionals and hospitals. We expect
most of the clustering at professional level and presume
an inclusion of a number of professionals per hospital
and a number of patients per professional. For prag-
matic reasons, we will include at most 12 out of the 20
hospitals of the current care measurement. This sample
of hospitals has to be representative for the Dutch
setting, i.e., a total of two university hospitals, six non-
university teaching hospitals, and four non-university,
non-teaching hospitals.
Data analysis
To assess the effectiveness of the implementation strategy,
the proportion of patients that are treated in accordance
with the guidelines before and after implementation of the
guidelines in both the intervention and control hospitals
will be measured. Medical outcome measures will include
CS rates and maternal as well as neonatal complications
related to vaginal delivery or CS. Multilevel multivariate
analysis will be carried out to assess the independent ef-
fect of the implementation strategy on adherence to the
CS quality indicators and medical outcome measures. A
qualitative descriptive analysis will be done in order to
evaluate the process. Furthermore, by means of a ques-
tionnaire, the experiences of healthcare providers and
patient satisfaction with the implementation strategy
will be evaluated, and the outcomes will be descriptive.
The costs analysis will be performed from a healthcare
perspective. The costs of the implementation process
will be calculated on the basis of the time and materials
invested based on activity-based costing (ABC) ap-
proach, focusing on activities performed with costs
accumulated at the activity level(s) of the healthcare im-
plementation processes. The costs of implementation of
the guidelines and consolidation consist of personnel
and material costs. The input of resources will be
assessed by collecting volumes of consumed resources,
and multiplying these by the price of each resource unit.
For collecting information on the input of the resources,
registration forms will be completed by the people
involved in the implementation and consolidation
process. The prices of each resource unit will be based on
standard costs [22], market prices, or self-determined
costs. The medical costs used in de cost analysis will in-
clude CS rates and maternal and neonatal complications
related to vaginal delivery or CS. The costs of implemen-
tation and costs of the changed medical care will be
weighed against the proportion of patients that are treated
according to the CS guideline, after implementation. The
cost-effectiveness of implementation will be expressed asthe incremental costs per extra patient treated according
to the CS guideline, compared to the ‘do-nothing’ strategy
(i.e., no implementation, for which data before implemen-
tation will be used).
Ethical considerations
The Medical Ethical Committee (CMO) of Maastricht
(azM/UM) approved this study protocol and declared
that no ethical approval was necessary (MEC 09-4-047).
Discussion
The CS rate in The Netherlands is comparatively low
compared to other countries, but it is increasing espe-
cially in the group of healthy women with a singleton
pregnancy in vertex position at term. One would expect
this to coincide with improved outcomes for mothers
and children, which is, however, not the case [5]. Al-
though many suggestions considering the reason for this
rise have been made, the answer is not yet clear. We
hypothesize that incomplete guideline adherence is a
possible cause for the current increase in CS rate. In this
study we will determine current Dutch care regarding
CS using quality indicators. We will use national as well
as international guidelines to select the recommendations,
resulting in at least a set of internationally accepted indi-
cators. Because we will also report the current CS rates
by classification into the internationally accepted Robson
Criteria, international comparison of incidences of CS
rates in different subgroups will be possible. In that way,
specific indicators and incidences of those indicators
might be applicable elsewhere. Furthermore, we will focus
on factors that influence guideline implementation, and
thus optimal care in the barrier and facilitator analysis.
Although earlier reviews claimed that multifaceted
strategies (combinations of many different interven-
tions) are often effective, Grimshaw found that a higher
number of intervention components was not related to
higher effectiveness [23]. It seems plausible that com-
bined interventions are only more effective than single
interventions, if these are addressed at the specific
barriers to change. This is also the conclusion of Chaillet
et al.: in the obstetric setting in general and the CS setting
in particular, prospective identification of efficient strat-
egies and barriers to change is necessary to achieve a
better adaptation of intervention and to improve clinical
practice guideline implementation [24].
This study will hopefully result in one or more target
groups with high incidence and low guideline adherence
and the evaluation of an implementation strategy to
improve care. For example, non-progressing labour is
known to be one of the major reasons to perform a CS.
Should guideline adherence in these women be low, an
intervention based both on informing women and
reminders on optimal care for caregivers could be an
Melman et al. Implementation Science 2013, 8:3 Page 7 of 8
http://www.implementationscience.com/content/8/1/3option. Another possible target group might be women
with a previous CS. Although in general, the VBAC rate
was previously reported higher in the Netherlands than in
some other countries, recent data are lacking. Improve-
ment of care for these women could consist of a decision
aid to improve counselling. Both types of interventions
are also possibly effective outside the Netherlands. The
ultimate aim of our study is to implement the national
and international evidence-based guidelines on CS in all
Dutch hospitals in order to reduce the incidence of CS
and improve the outcome for mother and child. Further-
more, this study provides a framework for future studies
to enable improvement of guideline adherence and reduc-
tion of the CS rate.
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